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Background: Medulloblastoma is the most common intracranial childhood malignancy and a genetically
heterogeneous disease. Despite recent advances, current therapeutic approaches are still associated with high
morbidity and mortality. Recent molecular profiling has suggested the stratification of medulloblastoma from one
single disease into four distinct subgroups namely: WNT Group (best prognosis), SHH Group (intermediate
prognosis), Group 3 (worst prognosis) and Group 4 (intermediate prognosis). BMI1 is a Polycomb group repressor
complex gene overexpressed across medulloblastoma subgroups but most significantly in Group 4 tumours. Bone
morphogenetic proteins are morphogens belonging to TGF-β superfamily of growth factors, known to inhibit
medulloblastoma cell proliferation and induce apoptosis.
Results: Here we demonstrate that human medulloblastoma of Group 4 characterised by the greatest overexpression
of BMI1, also display deregulation of cell adhesion molecules. We show that BMI1 controls intraparenchymal invasion in
a novel xenograft model of human MB of Group 4, while in vitro assays highlight that cell adhesion and motility are
controlled by BMI1 in a BMP dependent manner.
Conclusions: BMI1 controls MB cell migration and invasion through repression of the BMP pathway, raising the
possibility that BMI1 could be used as a biomarker to identify groups of patients who may benefit from a treatment
with BMP agonists.
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Medulloblastoma (MB) is a highly aggressive embryonic
tumour of the cerebellum, and the most common paediat-
ric malignant brain tumour. Despite significant advances
in treatment, MBs are still associated with significant mor-
tality and high morbidity. Current therapeutic interven-
tion involves maximum surgical resection, cranio-spinal
irradiation and dose-intensive chemotherapy, which often
leads to severe secondary disabilities among the survivors
and, importantly, does not take into account the specific
molecular mechanisms driving tumour growth. Improved* Correspondence: s.marino@qmul.ac.uk
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stated.risk stratification of patients prior to therapy in addition
to novel molecularly tailored drugs are therefore urgently
needed to improve the prognosis of children with MB.
Recently, genome-wide expression analysis has signifi-
cantly advanced our understanding of the molecular
pathogenesis of MB, identifying four distinct molecular
subgroups affecting prognosis and predicting response
to therapy [1-4]. Two groups, characterized by activation
of WNT and Sonic Hedgehog (SHH) pathways respect-
ively, have been thoroughly characterized, while the mo-
lecular signatures underlining Groups 3 and 4 are less
well defined. WNT subgroup tumours have the best
prognosis and while Group 3 represent the most malig-
nant molecular variant, associated with the worst patient
outcome, both SHH Group and Group 4 represents sub-
groups with an intermediate prognosis [5]. Metastatictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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semination via the cerebrospinal fluid, is an important,
independent adverse prognostic factor, present in up to
35% of patients at the time of diagnosis [6]. Higher in-
cidence of metastatic disease is found among MB of
Groups 3 and 4 and it contributes to their poor prog-
nosis [5].
Cerebellar development is guided by a complex net-
work of molecular and cellular mechanisms critical for
embryonic and postnatal development, while deregula-
tion of these pathways plays an essential role in MB for-
mation [7]. BMI1 is a potent inducer of neural stem cell
self-renewal and neural progenitor cell proliferation dur-
ing development and in adult tissue homeostasis. BMI1
overexpression is observed in numerous human cancers,
including MB [8]. We recently reported that BMI1 is
most highly expressed in Group 4 MB, a molecular
group with the lowest expression levels of TP53 [9]. In
support of these findings, overexpression of BMI1 with
concomitant Tp53 loss in the granule cell lineage in-
duces MB formation, albeit at very low frequency [9].
Bone morphogenetic proteins (BMPs) of the trans-
forming growth factor-β (TGF-β) superfamily are nega-
tive regulators of cell proliferation and cell survival in
the developing brain [10]. Activated BMP receptors
(BMPR) phosphorylate Smad1, Smad5 and Smad8 pro-
teins, which in turn results in Smad4 nuclear transloca-
tion, where it acts as a transcriptional regulator [11].
During cerebellar development, BMP2 and BMP4 inhibit
SHH-induced granule cell progenitors (GCPs) prolifera-
tion in vitro, resulting in differentiation, whereas BMP7
has the opposite effect [12,13]. BMP signalling remains
intact in MB cells [13] and exogenous BMP2 induces
apoptosis in a dose and time dependent fashion in pri-
mary human MB cells [14,15]. Moreover, BMP2 indu-
cing agents such as retinoic acid have been shown to
reduce MB tumour growth in vitro and in vivo [16].
Recently, we demonstrated in a genetically engineered
mouse model that BMI1 controls cellular interactions be-
tween granule and glial progenitors during cerebellar de-
velopment through repression of the BMP pathway [17].
In this study, we use a novel xenograft model of Group
4 MB and in vitro assays to assess the implications of
this novel molecular connection for MB pathogenesis.
Methods
MB cell lines and primary cells
MB cell lines (UW228-2, D-425, D-458, D-341 and
DAOY) were obtained from ATCC. DAOY and D-458
were used for functional studies: DAOY were grown as
adhesive monolayer while D458 were grown in suspen-
sion. Both cells lines were cultured and maintained in
Improved MEM media (Gibco) containing L-lysine and
Glutamate, supplemented with 10% FBS (Gibco), Penicillin(Sigma) 10 U/ml and Streptomycin (Sigma) 0.01 mg/ml.
For passaging, DAOY cells were trypsinised with 1% Tryp-
sin EDTA (Gibco).
Primary human MB cells (ICb-1299) were obtained
from Dr Xiao-Nan Li, Baylor College of Medicine, Texas
Children’s Cancer Centre, USA. These cells were origin-
ally isolated from an anaplastic MB, stage M3 and main-
tained as intracerebellar xenografts in mice after
orthotopic transplantation of fresh tumour [18]. Genetic
profiling of the original tumour and primary cells classi-
fied them as Group 4 MB [19]. For expansion and knock
down studies, these cells were cultured in Dulbecco’s
Modified Eagle Medium (D-MEM) with high glucose
(Gibco) supplemented with 10% FBS (Gibco), Penicillin
(Sigma) 10 U/ml and Streptomycin (Sigma) 0.01 mg/ml.
MB gene expression profiling and pathway analysis
Transcriptional profiling of BMI1kd versus wild-type
MB cell lines (DAOY) on Affymetrix Gene Chip Gen-
ome 133 2.0 Plus Expression arrays were downloaded
from Gene Expression Omnibus (GSE7578). Similarly,
human primary MB expression data across a 285 tu-
mours previously profiled on Affymetrix Human Gene
1.1ST arrays were downloaded from GSE37382. All CEL
files were analysed using Affymetrix Expression Console
(Version 1.1) as previously described in Northcott et al.
[3]. Genome-wide statistically significant differences in
gene expression patterns were calculated using the Wil-
coxon Rank Sum Test with Benjamini-Hochberg FDR
correction (q < 0.01) in MultiExperiment Viewer (MeV).
Statistically significant gene sets were further filtered on
the basis of absolute fold-changes greater or equal to
1.5. Pathway analysis was performed using GSEA Mo-
lecular Signature Database (MSigDB) using the curated
pathways described, and an FDR q-value below 0.05.
Unsupervised hierarchical clustering of BMI1-high, TP53-
low versus BMI1-low, TP53-low Group 4 medulloblasto-
mas was performed using the top 1500 genes with the
highest standard deviation using the Pearson Correlation
metric and bootstrapping as described previously [3].
RNA interference
BMI1 knock down (BMI1kd) was achieved either by
means of siRNA (transient) or shRNA (stable) technol-
ogy. For transient BMI1kd, FlexiTube siRNA (Qiagen)
specific for BMI1 (containing a mix of Hs BMI1 1, Hs
BMI1 2 and Hs PCGF4 3) was used. All Stars Negative
siRNA (Qiagen), referred to as scrambled (Scr) was used
as control. 70-80% confluent DAOY or D-458 cells were
treated with siRNA at a final concentration of 30nM in
combination with HiPerFect Transfection Reagent (Qia-
gen) according to manufacturer’s protocol. The trans-
fected cells were incubated for 48 hr prior to functional
studies for best knock down efficiency, as assessed by
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human GIPZ lentiviral shRNAmir BMI1 construct
(Open Biosystems) containing a CMV-driven GFP re-
porter and seven clones of target sequences of human
Hs BMI1 (NM_005180) was used. The plasmids (human
GIPZ shRNAmir BMI1 construct, pGIPZ empty vector,
HIV1 and VSVG) were first purified using QIAfilter
maxikit (Qiagen), then packaged using HEK293T cells to
produce lentiviral viruses with a final titre of 2.5 – 11 ×
108 TU/ml. Scr vectors were packaged with pGIPZ
empty transfer vector, as described above. DAOY and
ICb1299 cells were infected after mechanical dissoci-
ation at a multiplicity of infection (MOI) of 12.5 and 25
respectively, incubated for 72 hr and FACS sorted for
GFP prior to further culture. The efficacy of knock down
was assessed by western blot and qRT-PCR analysis at
multiple time points after passaging. BMI1 knock down
studies on DAOY and D-458 MB cell lines to investigate
BMP pathway activation by immunofluorescence and to
demonstrate cell aggregate formation were performed
using siRNA method, all other experiments were con-
ducted with a lentiviral mediated shRNA method. All
experiments were conducted at least in triplicates.
BMP pathway activation and inhibition
To induce BMP pathway, recombinant human BMP-4
(R&D systems) was used to treat the cells at a concen-
tration of 100 ng/ml for 24 – 36 h. To inhibit the BMP
pathway, mouse recombinant Noggin/Fc Chimera (Sigma)
was added to the cultures at a concentration of 1 μg/ml
and the cells were incubated for a minimum of 24 h prior
to functional analysis. When required, BMI1 kd was car-
ried out concomitantly as previously described.
Western blotting and qRT-PCR
Total protein were extracted from the cell pellets with
RIPA buffer, Tris HCL, NaCl, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS and protease inhibitors and soni-
cated. 25 μg of protein homogenates were separated by
acrylamide gel electrophoresis along with protein standard
ladder (Bio-Rad), transferred onto nitrocellulose mem-
brane by further electrophoresis, according to standard
protocols. The membrane was pre-incubated with 5% w/v
milk solution for 1 hr, followed by incubation with pri-
mary antibodies, either mouse monoclonal anti-BMI1
(Millipore) 1:500, rabbit polyclonal anti-pSMAD1,5,8 (Cell
Signalling) 1:1000, rabbit polyclonal anti-SMAD1,5,8 (Sant
Cruz Biotechnology) 1:400 or mouse monoclonal anti-
alpha-tubulin antibody (Sigma) 1:5000. Appropriate sec-
ondary antibodies, ECL peroxidase labelled anti-mouse
antibody (Millipore) 1: 3000, horse radish peroxidase anti-
rabbit IgG (Santa Cruz Biotechnology) 1:3000 were used
for detection, followed by detection of HRP using En-
hanced Chemoluminiscence substrate (Thermo Scientific).Total RNA was extracted from the cell pellets using
RNeasy microkit (Qiagen). Reverse Transcription was
carried out using Quantitect kit (Qiagen) and triplicates
of cDNA templates were subjected to TaqMan gene ex-
pression analysis according to standard protocols (BMI1
primer Hs00180411_m1 and housekeeping gene beta-
actin primer Hs99999903_m1, Applied Biosystems run
on a SDS 7500 system).
In vitro migration assays
Transwell migration assay: This assay was performed as
per published protocols [20,21]. Transwell® inserts
(24 mm diameter with pore size of 8 μm, Corning) were
first coated with basement membrane or ECM sub-
strates - Matrigel 100 μg/ml (BD Biosciences) or Type I
Collagen (First Link) 20 μg/ml. The coating procedure
was performed as per the manufacturer’s protocol, and
were left overnight at 37°C for adequate coating after
which the excess extract solution was carefully removed.
A constant number of cells (4 × 105 cells/well in 2 ml
serum free media) were incubated on the top surface of
these inserts placed in culture plate chambers. Media
containing 10% serum (chemoattractant) was added to
the bottom of the chamber. After incubating for 12 hr,
the cells in the inserts were fixed using 4% PFA and
stained with Gill’s Hematoxylin. Non-migrated cells
from the top surface of the insert membrane were
scraped, preserving only the migrated cells on the bot-
tom part of the membrane. Nuclei of migrated cells were
counted in 5 random 20X fields in each membrane using
ImageJ software. The values were expressed as mean ±
SD. All experiments were conducted in triplicates.
Gap closure assay [21]: A constant number of cells
(0.5 × 105 cells/well) were plated in a 24-well plate with-
out ECM substrate until they reached confluence. A
wound was incited (using a 20 μl pipette tip) in each
well by removing ~80 μm wide strip of cells. The
wounded monolayer was washed with medium to re-
move floating cells. The cells were incubated in time
lapse chamber (37°C and 5% CO2) and image acquired
(using Nikon inverted microscope, 20X lens) every hour,
for 12 hr. Three random areas for each well were im-
aged, and 3 set of wells were analysed for each condition
tested. The images were compiled and a movie was cre-
ated using Metamorph software (Molecular Devices,
Sunnyvale, California). The area of gap closure was mea-
sured as mean ± SD. All experiments were conducted in
triplicates.
Individual cell motility assays: The assay was per-
formed as per published protocols [22]. Ten cells in each
well were tracked by means of Metamorph software
(Molecular Devices, Sunnyvale, California) using image
acquired from time lapse microscopy (Nikon) and the
distance of migration was calculated and expressed as
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The experiments were conducted in triplicates.
Analysis of proliferation and apoptosis
The CyQUANT® NF proliferation assay kit (Invitrogen)
was used. The cells were plated in Costar® 96 well plate
(Corning Inc.) at a constant density of 103 cells per well
in 100 μl medium and were incubated at 37°C overnight
to achieve cell adherence. Initially, 1X Dye Binding solu-
tion was prepared by mixing 1X Hank’s balanced salt so-
lution (HBSS buffer) with Dye Reagent (containing
digitonin and dimethylsulfoxide), as per manufacturers
protocol. The medium was then removed and replaced
by 100 μl of 1X Dye Binding solution in each well. The
plate was incubated at room temperature for 30 min and
the fluorescence intensity (excitation set at 480 ±10 nm,
and emission detection at 530 ± 10 nm) of each sample
was measured by Synergy HT microplate reader (BioTek)
using KC4™ v3.4 software (BioTek). Three independent
experiments with three technical replicas each were
performed.
In addition, the proliferation capacity was also assessed
by means of growth curve analysis. The DAOY cells
(100,000) were seeded in a 6 well plate and incubated
for 2–3 days until they reached confluence of 75-85%,
after which they were trypsinised and the live cells
counted using Neubauer chamber. The total number of
cells at each passage was plotted on a growth curve. The
procedure was repeated over 7 consecutive passages
(14 days) with three biological replicas.
Apoptosis was analysed using PE Annexin V Apoptosis
Detection Kit I (BD Pharmingen™, BD Biosciences) as per
manufacturer’s protocol. Results were analysed by flow cy-
tometry (BD FACS Canto II analyser) and the percentage
of early apoptotic cells was determined using FACS Diva™
v6.1.3 software (BD Biosciences). Average percentage of
three independent experiments was used for analysis.
Ex vivo organotypic cerebellar slice culture
Organotypic cerebellar slices were prepared from C57BL/
6 P4-P6 pups, essentially as described in [23]. The cerebel-
lum was isolated and the meninges were carefully re-
moved in ice cold Hank’s Balanced Solution (Sigma)
supplemented with 45% glucose (Sigma) and Amphoteri-
cin B (Sigma). The cerebellum was then sagittally sec-
tioned at 420 μm thickness using a McIlwain tissue
chopper (The Mickle Lab. Engineering Co. Ltd.). The
slices were kept cold for further 1 hour to prevent overt
gliosis, and then 3–5 slices were placed on Millicell-CM
inserts (Millipore). The inserts were transferred to Petri
dish containing Modified Eagle’s Media (Sigma) and
Hanks Balanced Solution (Invitrogen) supplemented with
horse serum (Gibco), glutamine (Gibco), 45% glucose
(Sigma) and Amphotericin B (Sigma).To facilitate co-culture, tumour spheres were generated
after harvesting cells from monolayer cell culture. For
DAOY cells, 0.5-1 × 106 cells were cultured in 10 ml
complete media in 25 ml screw-top culture flasks and
maintained at constant rotation of 70 rev/min on an or-
bital shaker, at 37°C until tumour spheres were obtained at
24 hr [24]. ICb1299 cells were cultured at 37°C in ultra-
low cluster 6-well plate (Costar) in Dulbecco’s MEM (Invi-
trogen) supplemented with F12, EGF, FGF, B27 and
penicillin-streptomycin until tumour spheres formed at
48 hr [25]. Tumour spheres of comparable size (at least 3–
5 spheres/slice) were then seeded on the cerebellar slice
cultures under stereomicroscopy and incubated for up to
8 days. The co-cultures were then fixed with 4% PFA, and
stained with DAPI. Tumour cells could be identified
because they were GFP positive upon lentiviral transduction
and images were captured with a Confocal 710 microscope
(Zeiss). Cell migration was assessed using two parameters –
i) percentage of invasion area, calculated as [(total area –
original tumour sphere area)/(total area) × 100], where total
area is the area of migration plus that of the original
tumour sphere, and ii) maximum distance of migration
(distance in μm from periphery of thetumour sphere to the
most distal migrated tumour cell) using Zen 2011 software
(Zeiss). Three areas were assessed on each slice and a total
of three slices were analysed for each experimental group.
All experiments were conducted in triplicates.
Immunocytochemistry and immunohistochemistry
Cells, cultured on Poly-lysine (PLL) coated coverslips,
were fixed using 4% PFA and pre-treated with 5% Nor-
mal Goat Serum, followed by incubation with primary
antibodies, either mouse monoclonal anti-BMI1 (Milli-
pore) 1:500 or rabbit polyclonal anti-pSmad1/5/8 (Cell
Signalling) 1:100. Appropriate fluorescent secondary
antibodies were used, goat anti-mouse 546 (red, Invitro-
gen) 1:400 or goat anti-rabbit 488 (green, Invitrogen)
1:400. The coverslips were counterstained with DAPI
and mounted on glass slides. Five random fluorescent
micrographs (20X magnification) were obtained using a
Leica DFC350 microscope. The total number of cells
(DAPI positive) and the number of pSmad1/5/8 or BMI1
positive cells were counted using ImageJ software. The
values were expressed as mean ± SD. The overlay pictures
were used to count the clusters of cells with the same
method. All experiments were carried out in triplicates.
Freshly frozen tissue sections (xenografts fixed with 4%
PFA and embedded in OCT) were initially treated with
cold methanol for 10 min followed by either 5% Normal
Goat Serum or 10% Normal Donkey Serum for 1 hr. They
were then incubated with either goat polyclonal anti-
BMI1 (Santa Cruz Biotechnology) 1:100 or rabbit poly-
clonal anti-pSmad1/5/8 (Cell Signalling) 1:100 primary
antibody overnight at room temperature. Appropriate
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Invitrogen) 1:400 or goat anti-rabbit 546 (red, Invitrogen)
1:400 for 2 hr at room temperature. The sections were
counterstained with DAPI and examined using Confocal
710 microscope (Zeiss).
For formalin fixed paraffin embedded tissue sections
antigen retrieval with microwave heat treatment in citric
acid monohydrate buffer of pH 6 was done. They were
pre-treated with 2.5% Normal Horse Serum (Vector) for
1 hr. Primary antibodies used were: rabbit polyclonal
anti-synaptophysin (DAKO) 1:200, rabbit polyclonal
anti-CD44 (Abcam) 20 μl/ml, mouse monoclonal anti-
Thrombospondin (Abcam) 1:25. Universal biotinylated
anti-mouse/anti-rabbit IgG (Vector) secondary antibody
was used. Vecstatin ABC reagent (Vector) and DAB re-
agent (Sigma) for 2–10 minutes was applied. All slides
were counterstained by Gill’s Hematoxylin and mounted
using DPX on glass cover slips.
In vivo orthotopic xenografts
All procedures had Home Office approval (Animals Scien-
tific Procedures Act 1986, PPL 70/7275). NOD-SCID P4-6
mice were anaesthetized according to standard procedure.
Tumour cells (105 cells resuspended in 2 μl sterile PBS)
were injected into the right cerebellar hemisphere (2 mm
lateral and 2 mm posterior to lambda, 2 mm deep) with a
26 gauge Hamilton syringe needle. Mice were culled when
developing neurological signs or at the end of the experi-
ment (12 weeks after transplantation). The cerebellum
and brain stem were harvested, fixed in 4% paraformalde-
hyde and cryopreserved in OCT. The entire cerebellum
and brain stem were serially sectioned at 20 μm thickness
and stained with DAPI. Every twelfth section was assessed
for GFP positivity under fluorescence stereomicroscope
(Nikon Eclipse 80i) using 10X (aperture 0.45) objective.
The tumour volume, as assessed by GFP positivity, was es-
timated in each cerebellum by Cavalieri probe (Ghulam
Muhammad et al. 2009, Villeneuve et al. 2005) using Stereo
Investigator 10 software (MicroBrightField, Inc.). The grid
points (20 μm grid spacing) overlapping the tumour areas
were counted and were converted into volume estimates
after accounting for the non-consecutive section interval
and section thickness. The maximum depth of invasion
(distance in μm, average of three areas) from the surface
into the cerebellum, brain stem and along the Virchow
Robin spaces were measured using ImageJ 1.43u software
(National Institutes of Health, USA).
Preparation, culturing and cell adhesion genes expression
analysis of GCPs
Cerebella were isolated from P7 control and Bmi1−/−
pups. Upon removal of meninges and blood vessels, cere-
bella were chopped with a mechanical tissue chopper
(400 μm thicknesses), followed by digestion with trypsinin HIB buffer (120 mM NaCl, 5 mM KCl, 25 mM HEPES
and 9.1 mM Glucose, pH 7.4) at 37°C for 12 min while
gently shaking. One ml of trypsin stopper (0.375%
Trypsin-inhibitor soybean, 0.3 mM MgSO47H2O, 0.125%
DNase I) was then added to stop the reaction and the
sample were quickly spun. The supernatant was discarded
and the pellet was resuspended with 10 ml of pre-
equilibrated culture medium (high Glucose DMEM with
10% FBS, 1% Glutamine, 1% P/S and 25 mM KCl in-
cluded). The tissue was then further triturated with a 10 ml
syringe and a 2 inch of 18 gauge needle for 5 times and
centrifuged for 12 min at 1000 rpm. The supernatant was
carefully removed and the cell pellet was resuspended in
fresh medium. The clumps of cells were left to settle down
for 120 s. The supernatant single cell suspension was trans-
ferred to a new 50 ml tube. Cells were seeded into 24-well
(0.4 × 106 cells/well) or 6-well (2.4 × 106 cells/well). 0.01%
PLL pre-coated coverslips were used when appropriate.
Bmi1−/− and control GCPs (n > 3), either untreated or
treated with Ng (1.0 μg/μl), were harvested after 24 h.
The cell pellets were lysed in RLT buffer from RNeasy
Mini purification kit (Qiagen, Valencia, CA) and the lys-
ate applied onto Qiagen shredder spin columns for
homogenization. Total RNA was isolated using RNeasy
purification kit and the extra On-column DNase Diges-
tion was carried out to remove genomic DNA. cDNA
synthesis was performed with RT2 First Strand Kit
(SABiosciences, US). Gene expression profiles of GCPs
were analysed with RT2 Profiler™ PCR Array Mouse
Extracellular Matrix and Adhesion Molecules (SABios-
ciences, US), the manufacturer’s protocol was strictly
followed. The Ct value of all the genes analysed were
normalized and the difference between BMI1−/− and
control samples were described by fold change. Student’s
T test was used for statistical analysis.
Statistical analysis
All in vitro and ex vivo experiments were performed at
least in triplicates. A minimum of 6 in vivo xenograft
models were used for each group for tumour volume and
invasion analysis, and three xenograft tumours from each
group were used for pSMAD1,5,8 expression analysis.
Mean values are presented with error bars corresponding
to ± SD. Statistical analysis was performed by using Prism
statistical analysis software (GraphPad). Significance is in-
dicated as ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05.
Results
Bmi1 dependent BMP pathway repression differentially
affects the expression of selected cell adhesion genes in
cerebellar granule cell progenitors
Using a genetically engineered mouse model, we recently
demonstrated that cell-cell interactions between granule
and glial progenitors are critically affected by Bmi1
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ition of BMP signalling [17]. As BMP signalling is known
to regulate cell-cell and/or cell-extracellular matrix
(ECM) interactions, thereby controlling cell motility
(reviewed in [26]), we set out to analyse whether Bmi1
could regulate the expression of cell-cell and cell-matrix
interaction genes in GCPs. GCPs were isolated from P7
cerebella of Bmi1−/− mice and control littermates, total
RNA was extracted after 1 day in culture (DIV1) and real
time PCR expression arrays were used to analyse the
expression of 84 genes related to cell adhesion. Eighteen
(n = 18) cell-cell/matrix interaction genes were expressed
at significantly higher level in Bmi1−/− GCPs (p < 0.05)
(Additional file 1: Table S1), of which 12 showed more
than 2-fold increase in their expression level (range 2.11-
5.68). These genes included Thrombospondin1, 2 and
Fibronectin, Fibulin, Collagens -type I, IV, V and VI, Lam-
inin α1 as well as CD44 and MMP 2, 8, 10.
Next, we set out to assess whether BMP pathway in-
hibition would affect the expression of Bmi1-regulated
cell adhesion and extracellular matrix genes. Cultures
were prepared from P7 cerebella of Bmi1−/− and control
littermates, in triplicate as previously described, and
were treated with Noggin prior to expression analysis.
Noggin (Ng) is a well-characterised inhibitor of BMP
signalling which competitively binds BMP cell surface
receptors [27]. We identified 4 Bmi1-regulated cell adhe-
sion genes whose expression was significantly (p < 0.05)
downregulated upon Noggin treatment (Additional file 1:
Table S1). These genes were Thrombospondin 2, CD44,
MMP10 and Collagen 6a1.
In agreement with the qPCR results, widespread up-
regulation of Thrombospondins was observed by immu-
nohistochemistry in GCPs (Figure 1A,D), granule cells
(Figure 1A,D and B,E and G,H) as well as in white mat-
ter glial cells (Figure 1C,F and G,H) in the cerebellum of
Bmi1−/− mice at P7 and P15. We observed similar expres-
sion patterns of CD44, although the differences between
mutant and controls were less prominent (Additional file 2:
Figure S1A-H).
Our data suggest that Bmi1 may regulate a subset of
cell adhesion genes through BMP pathway repression
during cerebellar development.
Expression of TGFβ-regulated cell adhesion molecules is
controlled by BMI1 in MB
Next we set out to examine whether BMI1-mediated re-
pression of the BMP pathway remains intact in MB.
Using a publicly available transcriptome-wide analysis of
DAOY MB cell line [28] we identified 1483 genes differen-
tially expressed (>1.5 fold change, P < 0.05) between
BMI1-shRNA knockdown (DAOYBMI1kd) and control MB
cells (Additional file 3: Table S2). A Molecular Signature
Databases (MSigDB) analysis identified over-representedcanonical pathways that included genes related to ECM-
receptor interactions as well as the TGFβ pathway
(Figure 1I). Importantly among the deregulated cell
adhesion molecules (ITGA3, LAMB3, LAMC1, COL7A1,
Thrombospondin 1 and CD44, Figure 1J), several either
represented the human homologue of the genes we had
identified in Bmi1−/− granule cell progenitors (Additional
file 1: Table S1) or belong to the same protein family.
To further establish the connection between BMI1
and TGFβ-regulated cell adhesion molecules identified
in murine GCPs and MB cell lines we examined gene
expression patterns across large cohorts of human pri-
mary MB samples (n = 282). Previously, we reported that
Group 4 MBs display the highest expression of BMI1,
relative to other molecular subgroups, while concomi-
tantly displaying the lowest TP53 expression [9]. Fur-
thermore, in animal models of this disease, while BMI1
overexpression alone is insufficient to initiate MB, BMI1
overexpression in the context of deletion of TP53 drives
MB formation [9]. Given the BMI1-high/TP53-low mo-
lecular signature associated with Group 4 MB (Figure 2A),
and the resultant phenotype observed in mouse models
recapitulating this genotype, we characterized the tran-
scriptional network associated with BMI1 expression in
this molecular subgroup. We identified two subgroups of
Group 4 MB on the basis of BMI1 expression levels (high
versus low) (Figure 2B), while concomitantly expressing
relatively low levels of TP53 to characterize the coopera-
tive events that may contribute to MB genesis. Thirty-two
percent (32%, 61/188) of Group 4 MBs analysed demon-
strate relatively high levels of BMI1 with concomitant re-
duced levels of TP53, whereas 18% of MBs demonstrate
relatively low levels of both BMI1 and TP53. Using un-
supervised hierarchical clustering (HCL) we demonstrate
that these two Group 4 molecular variants (BMI1-high,
TP53-low versus BMI1-low, TP53-low) cluster apart sug-
gesting that a distinct transcriptome-wide gene signature
associate with the expression of BMI1 (Figure 2C). A tran-
scriptome wide analysis of BMI1-high, TP53-low versus
BMI1-low,TP53-low Group 4 tumours revealed 542 genes
with a statistically significant (q < 0.01) and differential
(1.5-fold) expression pattern (Additional file 4: Table S3).
The affected genes largely cluster into Gene Ontology
(GO) families localized to the plasma membrane and in-
volved in signal transduction, and cell-to-cell signalling
(Figure 2D, Additional file 5: Table S4). Furthermore, our
analysis identified some of the same cell adhesion mole-
cules observed as differentially expressed in Bmi1−/−
GCPs and human MB cell lines upon BMI1 knockdown,
including: THBS1 (+2.44), Laminin B1 (LAMB1, -1.93,
Figure 2E), EFEMP2 (+1.71), FBN2 (+2.21), SMC3 (1.53),
Thrombospondin 4 (THBS4, +2.12, Figure 2E).
These data suggest that BMI1 may exert its role in hu-
man MB pathogenesis at least in part through modulation
Figure 1 BMI1 regulates the expression of cell adhesion genes in GCPs and ECM remodelling and TGFβ signalling in DAOY MB cells.
(A-H) Thrombospondin 1/2 immunohistochemistry on murine P7 cerebella show increased expression in GCPs in Bmi1−/− mice (D and E)
compared to the control cerebellum (A and B), higher magnification is shown in the inset. Increased expression of Thrombospondin 1/2 is also
seen in the white matter glial cells of Bmi1−/− (F) compared to P7 controls (C). Granule cells in the IGL of Bmi1−/− P15 mice also display
increased Thrombospondin 1/2 expression (H) as compared to control (G), inset show higher magnification. (I) Molecular Signature Database
(MSigDB) analysis of genes differentially expressed between DAOYBMI1kd versus control cells identifies significantly (FDR q < 0.05) over-represented
pathways [25]. (J) Heat map representation of the relative upregulation of ECM receptor signalling genes (upper panel) and silencing of TGF-beta
signalling (lower panel) in DAOYBMI1kd compared to control cells. Genes were identified using MSigDB and plotted to highlight differences in
expression of 3 z-scores or greater between the two groups (red = relative upregulation, blue = relative downregulation). EGL: External granular
layer, IGL: Internal granular layer, WM: White matter. Scale bar is 125 μm (A, D, G, H) and 80 μm (B, E, C, F) and 50 μm (B inset, E inset, G inset, H inset).
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Figure 2 Deregulated expression of cell adhesion molecules in BMI1-high; TP53-low Group 4 MB. (A) Box plot representation of BMI1
expression across a cohort of 282 primary MB profiled on Affymetrix 1.1ST gene arrays. BMI1 was significantly overexpressed in Group
4 MBs versus other molecular subgroups (p = 9.18e-12). Conversely, TP53 was significantly downregulated in Group 4 versus other
molecular subgroups (p = 1.18e-25). (B) Z-score analysis of 282 non-WNT primary MBs revealed 32%, (61/188) of Group 4 MBs dem-
onstrated relatively high levels of BMI1 with concomitant reduced levels of TP53, whereas 18% of MBs demonstrated relatively low
levels of both BMI1 and TP53. Between these two populations there was a statistically significant difference in BMI1 expression, of
1.76-fold. (C) Unsupervised hierarchical clustering (HCL) of the top 1500 most differentially expressed genes demonstrated that these
two Group 4 molecular variants (BMI1-high, TP53-low versus BMI1-low, TP53-low) largely cluster apart. (D) Molecular Signature Data-
base (MSigDB) analysis of differentially expressed genes between BMI1-high, TP53-low versus BMI1-low, TP53-low Group 4 MBs identi-
fied significantly (FDR q < 0.05) over-represented Gene Ontologies (GO) intrinsic to the plasma membrane and critical for cell
migration (E) Box plot representation of the expression of thrombospondin and laminin family members in BMI1-high, TP53-low ver-
sus BMI1-low, TP53-low Group 4 MBs identified in Bmi1−/− GCPs and human MB cell line upon BMI1 knockdown.
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BMP pathway repression.
BMI1 represses the BMP pathway in MB cell lines and in
primary Group 4 MB cells
BMI1 is expressed in several MB cell lines (Figure 3A),
at levels comparable to those observed in human
tumour tissue samples [8]. Conditions for effective BMI1
knock down were established for two extensively charac-
terized cell lines, DAOY and D458, with both transient
lipofection-mediated siRNA delivery and stable lentiviral-
mediated shRNA delivery (Figure 3B and Additional file 2:
Figure S2). MB cell lines were chosen to begin our analysis
because 1) they are very well characterised, extensively
used, amenable to manipulation of gene expression and 2)
a functional analysis in these cells would match the pub-
licly available expression analysis dataset we have used for
data mining [28].
Phosphorylation of SMAD1/5/8 is the main functional
indicator of BMP pathway activation [11] and its detec-
tion is commonly used to assess pathway status. In-
creased phosphorylation of SMAD1/5/8 in relation to
total SMAD1,5,8 was observed in DAOYBMI1kd as com-
pared to DAOYScr (Figure 3C).
Next, we used short-term cultures from a MB of
Group 4, maintained as an intracerebellar xenograft,
here referred to as ICb1299 [19]. We demonstrated that
ICb1299 expressed BMI1 at levels comparable to those
detected in DAOY (Figure 3D) and that lentiviral medi-
ated shRNA delivery efficiently silenced BMI1 expression
(Figure 3E). Furthermore, we showed increased phosphor-
ylation of SMAD1/5/8 in relation to total SMAD1,5,8 also
in these short term MB cultures upon BMI1 silencing
(Figure 3F), in keeping with a scenario where BMI1 re-
presses BMP pathway in human MB cells.
BMI1 controls cell migration of primary MB cells in an
ex vivo organotypic cerebellar slice co-culture assay
Organotypic slice cultures originally developed to study
neuron-specific interactions and neuronal development
of the cerebellum in vitro, retain some aspects of the
anatomical complexity of the developing cerebellum and
have been also successfully used to study and quantify
invasion, proliferation and angiogenesis of established
glioma cell lines [23,29].
We prepared organotypic cerebellar slices of 420 μm
nominal thickness from the cerebellum of C57BL/6 P4-6
pups and cultured them on porous membranes in a
chamber containing medium for a minimum of 24
hours. ICb1299 were maintained as tumour spheres in
culture for few passages to amplify the culture and to ef-
fectively knock down BMI1. For the purposes of compari-
son, DAOY were also cultured as tumour spheres for this
specific experiment. Tumour spheres of comparable sizefor each cell type were transferred onto the surface of
viable slices and co-cultured with the slices for 8 days
(Figure 3G). MB cells were identified taking advantage of
the GFP labelling conferred to them by the lentiviral in-
fection. The original tumour spheres were identified
based on morphology and cell migration was assessed by
analysing the maximum distance of migration from the
edge of the tumour sphere and the percentage change in
migration area [23]. After 8 days of co-culture, both
DAOYBMI1kd and ICb1299BMI1kd demonstrated a reduced
area of migration 43.63% (± 6.06) vs. 64.23% (± 7.83) in
DAOY (p = 0.021) and 35.34% (± 2.64) vs. 48.19% (±
3.74) in ICb1299 (p = 0.008); and a reduced distance of
migration as compared to control shRNA scr treated
cells - 157.40 μm (± 23.38) vs. 250.03 μm (± 34.71) in
DAOY (p = 0.017), and 80.50 μm (± 23.37) vs. 115.28 μm
(± 34.71) in ICb1299 (p = 0.041) (Figure 3H,I,J).
These data show that the migratory properties of MB
cells are influenced by BMI1 expression in both MB cell
lines and in short term cultures of MB Group 4.
Tumour volume and parenchymal invasion but not
leptomeningeal spreading is controlled by BMI1 in an
orthotopic MB xenograft model
To determine the contribution of BMI1 to tumour
growth and invasive characteristics, DAOYBMI1kd and
ICb1299BMI1kd as well as their control counterparts were
transplanted into the cerebellum of P4-6 NOD-SCID
pups. Twelve weeks after transplantation, mice were
sacrificed and the cerebellum, brain stem and spinal
cord were analysed histologically (Figure 4A). Histo-
logical examination identified multifocal tumour growth
composed of poorly differentiated neoplastic cells with
densely packed round to oval cells with hyperchromatic
nuclei surrounded by scanty cytoplasm (Figure 4B,C)
and diffuse expression of synaptophysin (Figure 4D). Im-
munohistochemical analysis confirmed prominent re-
duction of BMI1 expression in tumours arising from
DAOYBMIkd and ICb1299BMI1kd cells as compared to those
arising from scrambled treated cells (Additional file 2:
Figure S3). 100% (18/18 mice) of mice injected with
DAOY cells either DAOYBMIkd or DAOYScr developed
intracerebellar xenografts, while 63.2% (12/19 mice) of
mice injected with ICb1299 cells developed tumours. No
significant difference in tumour engraftment was observed
between ICb1299Scr and ICb1299BMI1kd injected mice
(60% vs. 66.6% respectively). Interestingly, however, esti-
mation of the tumour volume by Cavalieri probe using
Stereo Investigator software (Figure 4E,F) revealed re-
duced total tumour volume in mice engrafted with
DAOYBMI1kd cells compared to those engrafted with
DAOYScr cells - 2.39 mm3 (± 1.63) vs. 5.18 mm3 (± 2.57),
p = 0.009, n = 9 in each category (Figure 4I) and similar
findings were observed in ICb1299BMI1kd xenografts as
GFP
Figure 3 (See legend on next page.)
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Figure 3 BMI1 represses the BMP pathway and controls cell migration of primary Group 4 MB cells and MB cell lines. (A) Analysis of
BMI1 protein expression in various MB cell lines. (B) Effective BMI1 knock down is seen in DAOY and D-458 48 hrs after treatment with BMI1
siRNA, as compared to siScr and Untreated (Untr) controls. (C) Increased phosphorylation of SMAD1,5,8 proteins (pSMAD1,5,8) as compared to
total SMAD1,5,8 is seen in DAOY cells following BMI1 shRNA treatment (shBMI1) as compared to shScr. (D) BMI1 protein expression is seen in
primary Group 4 MB cells (ICb-1299), and the expression levels are comparable to that of DAOY. (E) An effective BMI1 knock down is achieved in
ICb-1299 primary cells following BMI1 shRNA treatment. (F) Increased pSMAD1,5,8 expression as compared to total SMAD1,5,8 is also seen in
ICb-1299 upon BMI1 knock down, indicative of BMP pathway activation. (G) Schematic of organotypic cerebellar slice co-culture used as an
ex vivo assay to study MB cell migration. The DAOY or ICb-1299 cell spheres are placed on the slices and allowed to migrate for 8 days.
(H) Confocal images at day 8 demonstrate migration of GFP labelled DAOY cells on the cerebellar slice. Reduced cell migration in shBMI1 (right)
compared to shScr treated (left) DAOY cells. (I and J) Decreased area of migration (I) and a decreased distance of migration (J) is seen in both
DAOY and ICb-1299 cells treated with shBMI1, compared to shScr controls. Three areas were assessed on each slice and a total of three slices
were analysed in each group (N = 3). Error bars in graphs represent SD. *, P < 0.05; **, P < 0.01. Scale bar is 250 μm. Abbreviations: GFP, Green
Fluorescent Protein; DAPI, 4′,6-diamidino-2-phenylindole.
Merve et al. Acta Neuropathologica Communications 2014, 2:10 Page 11 of 18
http://www.actaneurocomms.org/content/2/1/10compared to ICb1299Scr - 3.35 mm3 (± 1.05) vs. 9.24 mm3
(± 3.09), p = 0.001, n = 6 in each category (Figure 4I).
Furthermore, assessment of the depth of invasion into
the cerebellar parenchyma from the pial surface revealed
a significant reduction for both DAOYBMI1kd and
ICb1299BMI1kd xenografts - 141.35 μm (± 51.51) vs.
216.61 μm (± 61.24) for DAOY (p = 0.008), and 159.74 μm
(± 34.96) vs. 239.49 μm (± 25.75) for ICb-1299 (p = 0.001)
(Figure 4G,H and J). Similar findings were recorded when
measuring depth of tumour cell invasion into the brain
stem [401.78 μm (± 126.41) DAOYBMI1kd vs. 575.83 μm
(± 175.91) DAOYScr (p = 0.018)] and 332.78 μm (± 39.23)
ICb1299BMI1kd vs. 459.09 μm (± 62.06) ICb1299Scr (p =
0.001) (Figure 4K). Instead, invasion along the (perivascu-
lar) Virchow Robin spaces (Figure 4L) and the leptomen-
ingeal spread (data not shown) were not affected.
To determine the BMP pathway status in the xeno-
grafts, we performed pSMAD1,5,8 immunohistochemi-
cal labelling on DAOYBMI1kd, DAOYScr, ICb1299BMI1kd
and ICb1299Scr tumours. The number of MB cells ex-
pressing pSMAD1,5,8 was increased in BMI1 silenced
xenografts - 38.27% (±6.16) vs. 16.02% (± 3.51) in DAOY
(p = 0.005), and 32.77% (±6.0) vs. 12.33% (±1.50) in ICb-
1299 (p = 0.004) (Figure 4M,N).
These observations show that BMI1 controls both
tumour size and parenchymal invasion in MB xenografts
and confirm that it represses BMP pathway activation
also in vivo.
Cell migration of MB cell lines is regulated by BMI1 in a
BMP pathway dependent fashion in vitro
The invasiveness of malignant cells has been linked to
their adhesive properties [30], raising the possibility that
the reduced migration and invasion observed upon
BMI1 knock down could be due to BMP-regulated
changes in cell adhesion. To test this hypothesis, we
used a modified Transwell Migration Assay and an
in vitro Gap Closure Migration Assay. In support of our
organotypic culture experimental results, we observed a
trend to form cohesive cell clusters in both DAOY andD-458 cell lines when cultured in vitro upon BMI1 silen-
cing. Quantification of the number of multicellular aggre-
gates, as defined by cohesive clusters of 10 or more cells
per 20x field, confirmed the morphological observation
that BMI1 knockdown significantly increased the number
of multicellular aggregates in both MB cell lines - 1.93
(+/− 0.31) vs. 0.07 (+/− 0.12) in DAOY (p = 0.004), and 3
(+/− 0.6) vs. 1.2 (+/− 0.2) in D-458 (p = 0.003) (Figure 5A,C).
Quantification of the number of pSMAD1/5/8 positive
cells in DAOYBMI1kd and D-458BMI1kd cultures confirmed
a significant increase in the number of positive cells
in both cell lines upon BMI1 knock down - 86.63%
(+/− 2.41) vs. 77.05% (+/− 3.25) in DAOY (p = 0.017) and
51.17% (+/− 1.74) vs. 36.06% (+/− 5.19) in D-458 (p =
0.004) (Figure 5A,B), in keeping with previous Western
blot results (Figure 3C). Treatment of DAOY and D-458
cultures with Ng revealed a significant reduction of the
number of pSMAD1/5/8 positive cells - 57.88% (± 2.85)
vs. 77.05% (± 3.25) in DAOY (p = 0.0007) and 23.69%
(± 7.19) vs. 36.06% (± 5.19) in D-458 (p = 0.036) (Figure 5B),
confirming the inhibitory role of Ng on BMP pathway
also in MB cell lines. When Noggin treatment was
applied to DAOYBMI1kd and D-458BMI1kd cultures, the
number of pSMAD1/5/8 positive cells was also reduced –
78.47% (± 1.35) vs. 83.63% (± 2.40) for DAOY (p = 0.006)
and 39.66% (± 1.35) vs. 51.17 (± 1.74) for D-458 (p =
0.0004) (Figure 5B). Under these culturing conditions, a
significant decrease in the number of cell aggregates was
observed for both DAOY and D-458 - 0.73 (+/− 0.30) vs.
1.93 (+/− 0.31) in DAOY (p = 0.004), and 1.07 (+/− 0.30)
vs. 3 (+/− 0.6) in D-458 (p = 0.003) (Figure 5C).
In the Transwell Migration Assay, MB cells cultured in
serum-free medium were plated on the top surface of a
substrate coated Transwell membrane (containing 8 μm
diameter pores), while medium containing 10% serum was
added to the bottom well as chemo-attractant. After incu-
bation for 12 h, the number of cells that migrated through
substrate and membrane were stained with Haematoxylin
and counted. Two different adhesion substrates were used
in separate experiments - matrigel (a basement membrane
DAPI
DAPI
Figure 4 (See legend on next page.)
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Figure 4 Tumour volume and parenchymal invasion is controlled by BMI1 in an orthotopic MB xenograft model. (A) Schematic showing
generation and analysis of orthotopic MB xenografts. (B-D) Histology of the ICb-1299 xenografts shows a multifocal poorly differentiated tumour
in the cerebellum, which show widespread Synaptophysin expression. (E-F) 2D representation of tumour volume estimates by Cavalieri probe
using Stereo Investigator software. The overlapping tumour areas marked during Stereomicroscopic evaluation are represented in red (20 μm grid
spacing used). (G-H) Confocal images showing a reduced intra-cerebellar invasion of GFP labelled ICb-1299 cells in shBMI1 xenograft (H) when
compared to shScr (G). The depth of invasion (μm) is measured from the deepest cell to the pial surface (dotted line) (N≥ 6 in each group).
(I) Quantification of tumour volume estimated by Cavalieri probe using Stereomicroscope, showing reduced volume (mm3) in shBMI1 group
compared to shScr group in both DAOY and ICb-1299 xenografts. (J-K) The average distance of invasion (μm) of tumour cells from the pial
surface into the cerebellar parenchyma (J), and into the Brain stem (K), show a reduction in shBMI1 groups in both DAOY and ICb-1299 xenografts.
However, the average distance of spread of tumour cell along the Virchow Robin space is not significantly different (L). The distances were quantified
using acquisitions from Confocal microscopy (N≥ 6). (M) pSMAD1,5,8 immunohistochemistry in ICb-1299 xenografts showing aberrant activation of
BMP pathway in ICb-1299BMI1kd (upper panel) as compared to ICb-1299Scr (lower panel) (N) Quantification of percentage of pSMAD1,5,8 expressing
cells in selected xenografts (N = 3). Scale bar 1 mm (B), 125 μm (C, D, G, H) and 50 μm (M). Error bars in graphs represent SD. *, P < 0.05; **, P < 0.01.
Abbreviations: H&E, Hematoxylin and Eosin; GFP, Green Fluorescent Protein; DAPI, 4′,6-diamidino-2-phenylindole.
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lagen. These substrates were chosen to mimic the in vivo
leptomeningeal environment, which mainly comprises
laminin and type I collagen in the matrix structure. DAOY
cells adhered well on these substrates and could be
assayed while D-458 cells did not adhere and were not
used for this experiment.
Whilst there was no significant difference in cell mi-
gration between the DAOYBMI1kd and DAOYScr on
matrigel substrate (data not shown), we observed a signifi-
cant reduction of migrating cells in DAOYBMI1kd cultures,
compared to DAOYScr on collagen type I substrate - 80.67
(+/− 55.51) vs. 176.07 (+/− 42.38), p = 0.005 (Figure 5D),
raising the possibility that Collagen type 1, which is known
to be expressed in the leptomeninges [31], represent a
more appropriate substrate for MB cell invasion. Import-
antly, decreased migration of DAOYBMI1kd cells was
dependent on aberrant activation of BMP pathway, as the
number of migrating cells significantly increased upon
Noggin treatment of DAOYBMI1kd cultures - 147.23
(+/− 46.63) vs. 80.67 (+/− 55.51), p = 0.004 (Figure 5D).
No significant difference in cell migration was noted
upon Noggin treatment of DAOYScr 129.58 (+/− 72.56)
vs. 176.07 (+/− 42.38), p = 0.081 (Figure 5D).
To validate the findings with an independent migra-
tion assay, DAOY cells were plated with optimum cell
density and an 800 μm wide linear gap was incited. The
area of gap closure was analysed using time lapse video-
microscopy over 12 hr. A significant reduction in the
gap closure area was observed in the DAOYBMI1kd
cultures as compared to DAOYScr cultures - 29.08%
(+/− 5.19) vs. 43.11% (+/− 6.47), p = 0.0025, an effect
that was reverted by additional treatment with Noggin -
40.18% (+/− 8.42) and 29.08% (+/− 5.19) respectively, p =
0.048 (Figure 5E). No significant difference in gap closure
was noted upon Noggin treatment of DAOYScr - 45.79%
(+/− 12.59) vs. 43.11% (+/− 6.47), p = 0.12 (Figure 5E).
Next, we asked whether the changes in cluster forma-
tion and in cell migration/wound healing upon BMI1downregulation could be influenced by the Ink4a-
mediated cell cycle control exerted by BMI1 in various
physiological and cancer-related contexts. In keeping with
existing literature [28], we show that BMI1 downregula-
tion significantly reduced proliferation of the DAOY cells,
as assessed by two independent methods, the CyQuant
fluorescence emission 280.55 ± 43.6 vs. 532.44 ± 51.6 units
(p = 0.003) and the growth curve analysis (Additional file 2:
Figure S4A and C). However, concomitant treatment of
DAOYBMI1kd with Ng did not rescue the proliferation de-
fect (Additional file 2: Figure S4A and C) and no signifi-
cant impact on apoptosis was noted upon Noggin
treatment of DAOYBMI1kd as assessed by Annexin V stain-
ing and FACS analysis [DAOYBMI1kd + Ng vs. DAOYBMIkd =
78.58% (+/− 10.77) vs. 80.13% (+/− 11.15), p = 0.434]
(Additional file 2: Figure S4B).
Taken together these results support the conclusion
that (i) BMI1-mediated control of proliferation is BMP-
independent and (ii) BMI1/BMP mediated control of cell
adhesion and migration is independent from the well-
known effect of BMI1 on cellular proliferation. In keep-
ing with this interpretation, single cell motility tracking
by time lapse microscopy confirmed reduced motility
in DAOY cells upon BMI1 knock down - 8.43 μm
(+/− 1.61) vs. 11.41 μm (+/− 1.69), p = 0.005 (Additional
file 2: Figure S5A-C)
BMP treatment of a MB cell line reduces cell migration in a
similar fashion to BMI1 knock down and no additive effect
is seen when BMP is applied after BMI1 knock down
We reasoned that BMI1-mediated repression of BMP
pathway could be the molecular mechanism which is
counteracted by treatment of MB cells with BMP. This
treatment has been shown to be effective on MB cell lines
both in vitro and in vivo, in mouse models [13]. DAOY
cells were treated with BMP4 (100 ng/ml concentrations)
and protein expression analysis for pSMAD1,5,8 in rela-
tion to SMAD1,5,8 demonstrated best pathway activation
between 24 h and 48 h after treatment (Figure 5F). This
Figure 5 (See legend on next page.)
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Figure 5 Cell migration of MB cell lines is regulated by BMI1 in a BMP pathway dependent fashion in vitro. (A) DAOY and D-458 cultures
show an increased number of cells (in %) expressing pSMAD1,5,8 and an increased number of cohesive cell clusters upon siRNA BMI1 treatment
(bottom panel) compared to siRNA Scr treatment (top panel). (B) Quantification of the number of cells expressing pSMAD1,5,8 in cultures with or
without Noggin treatment (N = 3). (C) Quantification of cohesive cell clusters per HPF with or without Noggin treatment (N = 3). (D) Transwell
migration assay shows a decreased migration of DAOY cells in shRNA BMI1 cultures compared to shRNA Scr, but when shBMI1 cultures are
concomitantly treated with Noggin, cell migration is rescued (N = 3). (E) Gap closure assay shows similar findings. (F) Western blot demonstrating
BMP pathway activation by means of increased pSMAD1,5,8 expression as compared to total SMAD1,5,8 in DAOY treated with BMP-4, compared
to untreated cells. (G) Transwell migration assay shows decreased migration of DAOY cells upon BMP-4 treatment similarly to shRNA BMI1 knock
down but no additive effect is seen when BMP4 treatment is applied concomitantly to shRNA BMI1 knock down (N = 4). Scale bar = 250 μm. Error
bars in graphs represent SD. *, P < 0.05; **, P < 0.01. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole.
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Migration Assay, which was carried out on DAOYScr and
DAOYBMI1kd treated with BMP4 as compared to un-
treated controls. As observed previously, reduction in mi-
gration was observed in DAOYBMI1kd as compared to
DAOYScr cultures – 65 (+/− 8.85) vs. 142.85 (+/− 24.26),
p = 0.001 (Figure 5G). Whilst a significant reduction in cell
migration was noted in DAOYScr treated with BMP4 as
compared to untreated cells - 75.8 (+/− 14.78) vs. 142.85
(+/− 24.26), p = 0.003 (Figure 5G), no additional reduction
of cell migration was seen in DAOYBMI1kd cultures treated
with BMP4 as compared to DAOYBMI1kd without BMP4
treatment - 61.84 (+/− 9.07) vs. 65 (+/− 8.85), p = 0.160
(Figure 5G).
These findings raise the possibility that expression of
BMI1 could represent a biomarker for MB which could
benefit from a treatment with small molecules acting as
BMP agonists.Discussion
Bmi1 plays an important role in the postnatal develop-
ment of the cerebellum and its deficiency leads to devel-
opmental defects affecting both the neuronal and glial
lineages in mice [8,17]. The best characterized function
of Bmi1 is the control of proliferation of undifferentiated
progenitor cells mainly through repression of the Ink4a/
Arf tumour suppressor gene locus [32,33], which in turn
regulates the activity of cyclin D, Cdk4/Cdk6 and p53
(reviewed in [34]). BMI1 is overexpressed in a significant
proportion of MB affecting a multitude of cellular pro-
cesses, of which SHH-driven MB proliferation has been
most extensively interrogated [8,35]. However, we have
recently reported that BMI1 also regulates cell adhesion
and migration of cerebellar progenitors through repres-
sion of the BMP pathway [17]. These findings are in
keeping with chromatin immunoprecipitation coupled
with microarray experiments which have shown BMPs
to be direct targets of BMI1 in fibroblasts [36] and also
with the results of a recent paper showing that fine-
tuning of the expression of direct effectors or inhibitors
of the BMP pathway, such as for examples Id1-Atf3, by
BMI1 occurs in adult neural progenitor cells [37].BMPs are members of the TGFβ signalling pathway
and their role during cerebellar development and in MB
pathogenesis is well characterized. BMP2 and BMP4
favour the switch from proliferation to differentiation of
GCPs by antagonizing the mitogen SHH and similarly
induce an anti-proliferative role in murine MB cells [13].
BMP-mediated regulation of cell adhesion and of the
cellular interactions with the extracellular matrix have
been demonstrated also in other cellular contexts such
as for example in soft tissues remodelling [38].
Here, we provide evidence that BMI1 controls tumour
volume and intraparenchymal invasion in an orthotopic
xenograft model of MB. While the reduced tumour vol-
ume observed upon BMI1 silencing follows previous re-
ports where reduced tumour growth was seen in
subcutaneous DAOY xenografts upon shRNA BMI1
knock down [28], the effect on brain invasion is novel.
Re-analysis of a publicly available genome wide expres-
sion dataset of BMI-1 knock-down MB cell lines re-
vealed deregulation of TGFβ pathway and differential
expression of several cell adhesion molecules. Aberrant
activation of BMP pathway in BMI1 silenced cells was
confirmed in our xenografts. These data together with
the results of the migration assays in vitro which show
that cell adhesion and motility are controlled by BMI1
through BMP pathway inhibition, raise the possibility
that this mechanism underpins also the phenotype
in vivo. Downregulation of BMI1 expression reduces
proliferation of MB cells and it is likely to contribute to
the reduced tumour volume observed in our xenografts
of DAOYBMI1kd cells. However, we show that BMI1-
mediated control of proliferation is BMP-independent
and it is therefore unlikely to be responsible for the ef-
fect on motility and invasion.
Overexpression of BMI1 is found preferentially in hu-
man MB of Group 4 and overexpression of Bmi1 induces
MB formation only in the context of Tp53 deletion in the
mouse, albeit at very low frequency [9]. We previously
reported that Group 4 MBs also display the lowest TP53
expression [9], although the mechanism for this is cur-
rently unknown, as genetic mutations of TP53 are more
frequent in other subgroups. It is conceivable, however,
that other mechanisms including epigenetic regulation,
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MBs [39], could be involved here and indeed low Tp53
levels may play a functionally very relevant role also in
Group 4 MBs. A biostatistical analysis of human Group
4 MB overexpressing BMI1 while concomitantly express-
ing low levels of TP53 revealed a set of differentially
expressed genes, which affected extracellular matrix struc-
tural constituents. Among these genes, members of the
Thrombospondin and Laminin families were detected,
which were deregulated also in DAOYBMI1kd and in GCPs
lacking Bmi1 in a BMP dependent fashion. GCPs and
cerebellar neural stem cells (cNSC) have been shown to
act as cell of origin of MB [40,41], in particular SHH
group MB originates from GCPs [42]. Little is known
about the cell origin of MB Group 4 but their origin from
GCPs is a distinct possibility as they could have lost SHH
dependency during their oncogenic transformation path-
way. It will be important to improve our mouse model of
MB Group 4 [9], for example with a conditional approach
to selectively inactivate TPp53 in the granule cell lineage
and to compare it with the human counterpart to validate
or dispute this theory. Alternatively, BMI1-mediated re-
pression of BMP could be a molecular feature of MB over-
expressing BMI1, independent of molecular subgroup
affiliation and cell of origin.
We show significant deregulation of extracellular
matrix gene expression in human MB overexpressing
BMI1. Among these genes, members of the Thrombos-
pondin, Laminin and Collagen families were regulated
by BMI1 in MB cell lines and in GCPs, in the latter case
in a BMP-dependent fashion. Thrombospondins are
strongly expressed in postmitotic premigratory GCPs
[43] where they bind to integrins, which are involved in
the control of GCPs proliferation in cooperation with
SHH, as shown in mice lacking integrin β1 [44]. Inter-
estingly type IV collagens induce expression of throm-
bospondins and the role of these matrix proteins in
regulation of differentiation of CNS progenitors has
been demonstrated [45]. Members of both the throm-
bospondin and [46] and collagen families [4] are deregu-
lated in human MB with an aggressive phenotype. Taken
together these data raise the possibility that invasion of
MB cells is regulated by BMI1 through BMP-mediated
control of cell adhesion. Interestingly we did not see in-
creased spreading of MB cells along VR spaces in our
xenograft model and tumours expressing high levels of
BMI1 were not associated with higher incidence of
spinal metastasis in human MB (data not shown), there-
fore implying that the molecular mechanisms regulating
intraparenchymal invasion and leptomeningeal spread
may be different.
Treatment of brain tumour stem cells isolated from
glioblastoma patients with BMP reduced their tumouri-
genic potential through inhibition of the proliferationcapacity and increased glial differentiation [47] and pro-
liferation arrest by BMPs has been shown also for MB
[13], raising the possibility that small molecules acting
as BMP agonists could be developed to be used thera-
peutically in MB patients. Importantly, we show that the
impact of BMP treatment on the invasive properties of
MB cells is most effective when BMI1 is expressed at
high levels, raising the possibility that BMI1 could be
used as a biomarker to identify groups of patients who
can benefit from a treatment with BMP agonists.
Conclusions
In this study, we used a novel xenograft model of Group
4 MB and in vitro assays to demonstrate that BMP path-
way activation is regulated by BMI1 in MB and controls
cell migration and invasion potentially by regulation of
extracellular matrix proteins.
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